Healthcare provider profile · identity verified

Lydia L Wolf, MD

Internal Medicine · AUSTIN, TX · NPI 1467433375

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	461	117
Atorvastatin Calcium	Atorvastatin Calcium	412	113
Amlodipine Besylate	Amlodipine Besylate	285	75
Lisinopril	Lisinopril	243	68
Losartan Potassium	Losartan Potassium	236	66
Sertraline Hcl	Sertraline Hcl	181	46
Metformin Hcl	Metformin Hcl	166	48
Zolpidem Tartrate	Zolpidem Tartrate	151	29
Metoprolol Succinate	Metoprolol Succinate	145	35
Pravastatin Sodium	Pravastatin Sodium	138	40
Gabapentin	Gabapentin	133	38
Pantoprazole Sodium	Pantoprazole Sodium	123	41
Hydrochlorothiazide	Hydrochlorothiazide	117	28
Omeprazole	Omeprazole	116	38
Alprazolam	Alprazolam	100	29
Simvastatin	Simvastatin	98	27
Rosuvastatin Calcium	Rosuvastatin Calcium	97	28
Montelukast Sodium	Montelukast Sodium	95	28
Metformin Hcl Er	Metformin Hcl	92	24
Escitalopram Oxalate	Escitalopram Oxalate	91	25
Valsartan	Valsartan	91	19
Fluoxetine Hcl	Fluoxetine Hcl	89	23
Clonazepam	Clonazepam	86	15
Tramadol Hcl	Tramadol Hcl	84	22
Albuterol Sulfate Hfa	Albuterol Sulfate	82	33
Bupropion Xl	Bupropion Hcl	81	21
Trazodone Hcl	Trazodone Hcl	77	29
Januvia	Sitagliptin Phosphate	75	17
Synthroid	Levothyroxine Sodium	75	21
Meloxicam	Meloxicam	73	34
Ozempic	Semaglutide	71	11
Duloxetine Hcl	Duloxetine Hcl	69	16
Fluticasone Propionate	Fluticasone Propionate	69	23
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	64	17
Carvedilol	Carvedilol	57	16
Ibandronate Sodium	Ibandronate Sodium	55	18
Furosemide	Furosemide	48	18
Valacyclovir	Valacyclovir Hcl	48	17
Citalopram Hbr	Citalopram Hydrobromide	47	12
Atenolol	Atenolol	45	12
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	44	13
Allopurinol	Allopurinol	41	suppressed
Lorazepam	Lorazepam	38	12
Benazepril Hcl	Benazepril Hcl	35	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	35	suppressed
Ropinirole Hcl	Ropinirole Hcl	35	12
Clopidogrel	Clopidogrel Bisulfate	34	suppressed
Jardiance	Empagliflozin	33	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Potassium Chloride	Potassium Chloride	33	13
Metoprolol Tartrate	Metoprolol Tartrate	32	11
Propranolol Hcl	Propranolol Hcl	32	suppressed
Glipizide Er	Glipizide	31	suppressed
Baclofen	Baclofen	29	suppressed
Diclofenac Sodium	Diclofenac Sodium	29	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	29	suppressed
Pregabalin	Pregabalin	28	suppressed
Estradiol	Estradiol	27	14
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	27	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	26	11
Irbesartan	Irbesartan	25	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	25	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	24	suppressed
Lovastatin	Lovastatin	24	suppressed
Spironolactone	Spironolactone	24	suppressed
Bupropion Hcl Sr	Bupropion Hcl	22	suppressed
Fluconazole	Fluconazole	22	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	22	suppressed
Methocarbamol	Methocarbamol	22	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	21	suppressed
Symbicort	Budesonide/Formoterol Fumarate	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	20	suppressed
Glimepiride	Glimepiride	20	suppressed
Ketoconazole	Ketoconazole	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	19	suppressed
Rizatriptan	Rizatriptan Benzoate	19	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Azithromycin	Azithromycin	18	18
Hydrocortisone	Hydrocortisone	18	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	18	suppressed
Verapamil Er	Verapamil Hcl	18	suppressed
Finasteride	Finasteride	17	suppressed
Glipizide	Glipizide	17	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Celecoxib	Celecoxib	16	suppressed
Mounjaro	Tirzepatide	16	suppressed
Temazepam	Temazepam	16	suppressed
Liothyronine Sodium	Liothyronine Sodium	15	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Ondansetron Hcl	Ondansetron Hcl	14	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	14	suppressed
Trulicity	Dulaglutide	14	suppressed
Donepezil Hcl	Donepezil Hcl	13	suppressed
Dropsafe Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Mitigare	Colchicine	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	12	suppressed
Alendronate Sodium	Alendronate Sodium	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	11	11
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Verapamil Sr	Verapamil Hcl	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error